Article Text

Download PDFPDF
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis
  1. Markku Hakala1,2,3,
  2. Kai Immonen4,
  3. Markku Korpela5,
  4. Mikko Vasala6,
  5. Markku J Kauppi3
  1. 1Department of Musculoskeletal Medicine and Rehabilitation, Medical School, University of Tampere, Tampere, Finland
  2. 2Rehabilitation Center, Päijät-Häme Central Hospital, Lahti, Finland
  3. 3Division of Rheumatology, Department of Medicine, Päijät-Häme Central Hospital, Lahti, Finland
  4. 4Department of Medicine, North-Karelia Central Hospital, Joensuu, Finland
  5. 5Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
  6. 6Department of Medicine, Kainuu Central Hospital, Kajaani, Finland
  1. Correspondence to Professor Markku Hakala, Division of Rheumatology, Department of Medicine, Päijät-Häme Central Hospital, Keskussairaalankatu 7, Lahti 15850, Finland; markku.hakala{at}

Statistics from

Incidence of reactive amyloidosis associated with rheumatic diseases is markedly decreasing1 as the presence of organ failure such as end-stage renal disease.2 However, we still encounter new cases of amyloidosis. While anti-TNF-α therapy may be effective in disease modifying antirheumatic drug (DMARD) resistant cases of amyloidosis, there are yet patients whose disease does not respond to that treatment.3 ,4

We searched for reports on tocilizumab (TCZ), an anti-interleukin-6 receptor (anti-IL-6R) antibody, as treatment for reactive amyloidosis registered in the PUBMED. Altogether six such cases were found with encouraging treatment results.3–8 All the reports are based on single case reports with limited follow-up data. We present over 1-year experience on five patients who were treated with the drug for this indication. One of the patients was included in our preliminary report of the effect of …

View Full Text


  • Contributors All the authors have given substantial contribution to: conception and design, or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content, final approval of the version to be published.

  • Competing interests ICMJE conflicts of interest for each author of this manuscript has been uploaded.

  • Ethics approval Provided by the Ethics committee of Rheumatism Foundation Hospital, Heinola, Finland.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.